<unk>  is an colony stimulating factor that is FDA approved for the treatment of to reduce the duration of severe neutropenia in patients with non‑myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia.   Common adverse reactions include Splenic rupture , Acute Respiratory Distress Syndrome , Serious Allergic Reactions , Capillary leak syndrome.
Tbo-filgrastim
Filgrastim
Pegfilgrastim
Romiplostim
Interferon Alfa-n3
Tositumomab
Aldesleukin
Interferon alfa-2a